Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia

Archives of Medical Science

Volumn 7, Issue 1, 2011, Pages 5-7

  Rizzo, Manfredi ^a   Rini, Giovam Battista ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Atherosclerosis; Cardiovascular risk; Dyslipidaemia; Ezetimibe

Indexed keywords

EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

AORTA STENOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; HETEROZYGOSITY; HUMAN; MONOTHERAPY; REVIEW; RISK REDUCTION;

EID: 79952514300     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2011.20597     Document Type: Review

References (15)

1. Mikhailidis DP, Wierzbicki AS, Daskalopoulou SS, et al. The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. Curr Med Res Opin 2005; 21: 959-69. (Pubitemid 40896244)
2. Neal RC, Jones PH. Complementary therapy to target LDL cholesterol: the role of the ezetimibe/simvastatin combination. Vasc Health Risk Manag 2006; 2: 31-8.
3. Paraskevas KI, Karatzas G, Pantopoulou A, Iliopoulos DG, Perrea D. Targeting dyslipidemia in the metabolic syndrome: an update. Curr Vasc Pharmacol 2010; 8: 450-63.
4. Angelopoulos J, Krassakopoulos N, Nathanson R, Boukas S, Sampalis JS. Co-administration of ezetimibe and a statin in management of dyslipidemias: a meta-analysis of clinical trials. Arch Med Sci 2009; 5: 347-363.
5. Kalogirou M, Tsimihodimos V, Saougos V, Lagos K, Tselepis AD, Elisaf M. Effect of ezetimibe on lipoprotein subfraction concentrations: the role of atorvastatin pretreatment. Arch Med Sci 2007; 3: 344-350. (Pubitemid 351212283)
6. Grigore L, Norata GD, Catapano AL. Combination therapy in cholesterol reduction: focus on ezetimibe and statins. Vasc Health Risk Manag 2008; 4: 267-78. (Pubitemid 351711955)
7. Kastelein JJ, Akdim F, Stroes ES, et al.; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431-43. (Pubitemid 351482735)
8. Rossebø AB, Pedersen TR, Boman K, et al.; SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359: 1343-56.
9. Rizzo M, Rini GB, Spinas GA, Berneis K. The effects of ezetimibe on LDL-cholesterol: quantitative or qualitative changes? Atherosclerosis 2009; 204: 330-3.
10. Rizzo M, Berneis K, Zeljkovic A, Vekic J. Should we routinely measure low-density and high-density lipoprotein subclasses? Clin Lab 2009; 55: 421-9.
11. Gazi IF, Tsimihodimos V, Tselepis AD, Elisaf M, Mikhailidis DP. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther 2007; 7: 53-72. (Pubitemid 46091576)
12. Berneis K, Rizzo M, Spinas, GA, et al. The predictive role of atherogenic dyslipidemia in subjects with non-coronary atherosclerosis. Clin Chim Acta 2009; 406: 36-40.
13. Rizzo M, Pernice V, Frasheri A, et al. Small, dense low-density lipoproteins are predictors of cardio- and cerebrovascular events in subjects with the metabolic syndrome. Clin Endocrinol 2009; 70: 870-5.
14. Mitka M. Cholesterol drug lowers LDL-C levels but again fails to show clinical benefit. JAMA 2010; 303: 211-2.
15. Cannon CP, Giugliano RP, Blazing MA, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008; 156: 826-32.